The Dually Acylated NH2-terminal Domain of Gi1alpha Is Sufficient to Target a Green Fluorescent Protein Reporter to Caveolin-enriched Plasma Membrane Domains
PALMITOYLATION OF CAVEOLIN-1 IS REQUIRED FOR THE RECOGNITION OF DUALLY ACYLATED G-PROTEIN alpha  SUBUNITS IN VIVO*

Ferruccio GalbiatiDagger §, Daniela VolontéDagger §, Davide Meani§, Graeme Milligan, Douglas M. Lublinparallel , Michael P. LisantiDagger **, and Marco Parenti§Dagger Dagger

From the Dagger  Department of Molecular Pharmacology and the Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York 10461, § Department of Pharmacology, School of Medicine, University of Milan, 20129 Milan, Italy,  Molecular Pharmacology Group, Division of Biochemistry and Molecular Biology, Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow G12 8QQ, Scotland, United Kingdom, and parallel  Department of Pathology, Washington University School of Medicine, St. Louis, Missouri 63110

    ABSTRACT
Top
Abstract
Introduction
References

Here we investigate the molecular mechanisms that govern the targeting of G-protein alpha  subunits to the plasma membrane. For this purpose, we used Gi1alpha as a model dually acylated G-protein. We fused full-length Gi1alpha or its extreme NH2-terminal domain (residues 1-32 or 1-122) to green fluorescent protein (GFP) and analyzed the subcellular localization of these fusion proteins. We show that the first 32 amino acids of Gi1alpha are sufficient to target GFP to caveolin-enriched domains of the plasma membrane in vivo, as demonstrated by co-fractionation and co-immunoprecipitation with caveolin-1. Interestingly, when dual acylation of this 32-amino acid domain was blocked by specific point mutations (G2A or C3S), the resulting GFP fusion proteins were localized to the cytoplasm and excluded from caveolin-rich regions. The myristoylated but nonpalmitoylated (C3S) chimera only partially partitioned into caveolin-containing fractions. However, both nonacylated GFP fusions (G2A and C3S) no longer co-immunoprecipitated with caveolin-1. Taken together, these results indicate that lipid modification of the NH2-terminal of Gi1alpha is essential for targeting to its correct destination and interaction with caveolin-1. Also, a caveolin-1 mutant lacking all three palmitoylation sites (C133S, C143S, and C156S) was unable to co-immunoprecipitate these dually acylated GFP-G-protein fusions. Thus, dual acylation of the NH2-terminal domain of Gi1alpha and palmitoylation of caveolin-1 are both required to stabilize and perhaps regulate this reciprocal interaction at the plasma membrane in vivo. Our results provide the first demonstration of a functional role for caveolin-1 palmitoylation in its interaction with signaling molecules.

    INTRODUCTION
Top
Abstract
Introduction
References

The alpha  subunits of heterotrimeric Gi, Go, and Gz proteins contain a common methionine-glycine-cysteine motif (MGC) at their extreme NH2 terminus. This MGC motif is also shared by most members of the Src family of non-receptor tyrosine kinases (NRTKs),1 with the exception of Src itself and Blk (1, 2). This motif represents a consensus sequence that specifies the covalent attachment of a 14-carbon lipid (myristate) and a 16-carbon lipid (palmitate) to glycine 2 and cysteine 3, respectively. Moreover, some NRTKs may possess an additional palmitoylated cysteine (e.g. cysteine 5 in Lck and cysteine 6 in Fyn). Point mutations that prevent myristoylation and/or palmitoylation of Galpha subunits and NRTKs drastically reduce the membrane avidity of these polypeptides, indicating that these lipid modifications act cooperatively to anchor these proteins to the cytoplasmic leaflet of the plasma membrane (3, 4).

Because myristoylation is an irreversible modification, it has been proposed that it may play only a passive role as a hydrophobic handle or appendage for anchoring Galpha subunits to membranes. In contrast, palmitoylation is a reversible modification and is therefore potentially regulatable, suggesting that it may play a more complex role in this process. In support of this hypothesis, palmitoylated Gzalpha and Gi1alpha are totally refractory to the GTPase-stimulating activities of the Galpha -interacting protein and the regulator of G-protein signaling 4. Thus, palmitoylation may represent a mechanism for prolonging or potentiating G-protein signaling (5).

Moreover, palmitoylation is required for a productive interaction between G-protein-coupled receptors and Galpha subunits. The myristoylated but palmitoylation-negative C3S mutant of Gi1alpha is unable to functionally couple with the alpha 2A adrenergic receptor co-expressed in transfected COS-7 cells, even when the concentration of the mutant in the membrane is equivalent to that of wild type Gi1alpha (6). One possible explanation for these results is that the C3S mutant of Gi1alpha might be segregated into a distinct plasma membrane compartment that is separated from where the receptor is located.

Recent evidence suggests that G-proteins are not homogeneously distributed throughout the cell surface. Instead, they may be concentrated within vesicle-like microdomains of the plasma membrane termed caveolae that exist in most cell types. It has been proposed that caveolae function as signaling depots where G-proteins and G-protein-coupled receptors, as well as other signaling molecules, are clustered (7-9).

Caveolae membranes fractionate as low buoyancy complexes on sucrose density gradients and are resistant to solubilization by nonionic detergents, such as Triton X-100, at low temperatures, due to their specialized lipid composition that is rich in cholesterol and glycosphingolipids (10, 11). The position of caveolae within these gradients can be tracked by immunoblotting with specific antibodies directed against the caveolin family of proteins, which are the principal structural protein components of caveolae membranes. Caveolins interact with each other to form homo- and hetero-oligomeric complexes, bind cholesterol, and interact with a variety of signaling molecules. For example, caveolin binding to Galpha subunits is sufficient to maintain them in the inactive GDP-liganded conformation (12-14). According to the "caveolae signaling hypothesis," Galpha subunits may become activated when G-protein-coupled receptors are recruited to caveolae upon agonist stimulation (15-17).

Recent studies have indicated that point mutations that abolish myristoylation and/or palmitoylation prevent the association of Gi1alpha and other dually acylated proteins (such as NRTKs and endothelial nitric oxide synthase) with caveolin-enriched membrane fractions (18-20). This raises the possibility that NH2-terminal lipid modification can also specify membrane compartmentalization of dually acylated molecules within caveolae by acting as a targeting signal and/or through direct interactions with the lipid or protein components of caveolae (e.g. cholesterol, glycosphingolipids, or caveolins).

To evaluate the potential role of the NH2-terminal region of Galpha subunits and its lipid modification in targeting to the plasma membrane, we constructed a variety of lipid-modified and non-lipid-modified fusion proteins using GFP. We examined their subcellular distribution by immunofluorescence microscopy and their ability to co-fractionate and co-immunoprecipitate with caveolin-1 using transient expression in COS-7 or 293T cells. In addition, we studied the behavior of GFP fused to a short caveolin-binding domain (21) recently identified within Galpha subunits (specifically, residues 186-200 in Gi1alpha ).

    EXPERIMENTAL PROCEDURES

Materials-- The GFP cDNA was a gift of Dr. J. Pines (Wellcome/CRC Institute, Cambridge, United Kingdom). It contains five mutations (F64L, S65T, V163A, I167T, and S175G) resulting in improved levels of fluorescence at 475 nm and is correctly folded at 37 °C. The cDNA encoding nonpalmitoylated caveolin-1 was as described previously (22). Antibodies and their sources were as follows: (i) anti-caveolin-1 IgG (mAb 2297 and mAb 2234; gifts of Dr. J. R. Glenney, Transduction Laboratories); (ii) anti-GFP IgG (rabbit polyclonal antibody; CLONTECH); and (iii) rabbit anti-Gi1alpha polyclonal anti-serum (I1C; raised against a synthetic peptide corresponding to amino acids 160-169 of the Gi1alpha subunit). [9,10-3H]Palmitic acid (40-60 Ci/mmol) and [9,10-3H]myristic acid (40-60 Ci/mmol) were from Amersham. All other biochemicals used were of the highest purity available and were obtained from regular commercial sources.

Construction of Gi1alpha -GFP Fusion Proteins-- To generate GFP fusion proteins, the cDNA encoding GFP was placed at the 3' end of the full-length rat Gi1alpha sequence (amino acids 1-355; FL-GFP) and of the following sequences of wild type rat Gi1alpha : (i) amino acids 1-32 (32aaWT-GFP), (ii) amino acids 1-122 (122aa-GFP), and (iii) amino acids 186-200 (caveolin-binding domain; CBD-GFP). Two additional constructs were generated by fusing GFP to the 1-32 NH2-terminal amino acid sequence of Gi1alpha : (i) 32aaG2A-GFP (mutation at the myristoylation site by replacing glycine 2 with alanine), and (ii) 32aaC3S-GFP (mutation at the palmitoylation site by substituting cysteine 3 with serine). Finally, GFP fusions were constructed in which the first 6 of 10 NH2-terminal amino acids of Gi1alpha were fused to GFP. All Gi1alpha -GFP fusion proteins were generated by polymerase chain reaction amplifications using the appropriate primers and subsequently subcloned in pcDNA3 expression vector (Invitrogen). The correctness of intended base substitutions and the absence of unwanted mutations were verified by DNA sequencing. All DNA manipulations, including ligations, bacterial transformation, and plasmid purification, were carried out using standard procedures.

Cell Culture and Transient Transfection-- COS-7 and 293T cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 µg/ml streptomycin, and 100 units/ml penicillin. Cells (30-50% confluent) were transfected using the calcium phosphate precipitation method and routinely analyzed 48 h after transfection.

Immunoblot Analysis-- Cellular proteins were resolved by SDS-PAGE (12.5% acrylamide) and transferred to nitrocellulose membranes. Blots were incubated for 2 h in TBST (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, and 0.2% Tween 20) containing 2% powdered skim milk and 1% bovine serum albumin. After three washes with TBST, membranes were incubated for 2 h with the primary antibody (~1,000-fold dilution in TBST) and for 1 h with horseradish peroxidase-conjugated goat anti-rabbit/mouse IgG (~5,000-fold dilution). Proteins were detected using the ECL detection kit (Amersham). For cell fractionation, cells were harvested and resuspended in 0.5 ml of hypotonic buffer (5 mM Tris-HCl, pH 7.5, 1 mM MgCl2, 1 mM EGTA, and 0.1 mM EDTA with 0.067 TIU/ml aprotinin (Sigma) and 0.2 mM phenylmethylsulfonyl fluoride (Sigma) as protease inhibitors). Cell suspensions were incubated on ice for 30 min, freeze/thawed, and homogenized with a Teflon/glass homogenizer. After a low speed centrifugation to remove unbroken cells and the nuclear pellet, samples were centrifuged for 30 min at 200,000 × g at 4 °C in a Beckman TL100 centrifuge. The pellets (particulate fraction) and the acetone-precipitated supernatants (soluble fraction) were separated by SDS-PAGE (12.5% acrylamide) and analyzed by Western blotting.

Metabolic Labeling and Immunoprecipitation-- After transfection, COS-7 cells were labeled for 4 h with [9,10-3H]palmitic acid (150 µCi/ml) or [9,10-3H]myristic acid (50 µCi/ml) in Dulbecco's modified Eagle's medium supplemented with 5% dialyzed fetal bovine serum, 5 mM sodium pyruvate, antibiotics, and L-glutamine. After washing with PBS, cells were lysed in 0.2 ml of 1% (w/v) SDS. After breakage of DNA by repeated pipetting and boiling for 4 min, 0.8 ml of the following mixture (Mix I) was added to each sample: 1.25% (w/v) Triton X-100, 190 mM NaCl, 6 mM EDTA, 50 mM Tris-HCl, pH 7.5, and protease inhibitors as indicated above. After centrifugation at 13,000 × g for 10 min at 4 °C, 2 µl of GFP antibody were added to each supernatant, and the samples were incubated overnight at 4 °C. Twenty-five µl of a 1:1 suspension of protein A-Sepharose CL-4B beads (Pharmacia Biotech Inc.) in Mix II (4 parts of Mix I plus 1 part of 1% SDS) were added to each sample and incubated for ~5 h at 4 °C with continuous rotation. Immunoprecipitates were washed three times for 15 min at 4 °C with Mix II (1 ml) and then washed once with 50 mM Tris-HCl, pH 6.8, and heated in Laemmli sample buffer (23) containing 20 mM dithiothreitol. Samples were separated by SDS-PAGE, and gels were treated with 2,5-diphenyloxazole for fluorography (24). To maximize sensitivity, we used a gel miniaturization procedure that involved soaking the 2,5-diphenyloxazole-impregnated gels after water washing in 50% (w/v) polyethylene glycol 3000 (Sigma) at 70 °C for 15 min before drying (25). Dried gels were exposed on Kodak X-Omat AR-5 films at -70 °C.

Fluorescence Microscopy-- Transfected 293T cells grown on glass coverslips were washed three times with PBS and fixed for 30 min at room temperature with 2% (w/v) paraformaldehyde in PBS. Fixed cells were rinsed with PBS and treated with 25 mM NH4Cl in PBS for 10 min at room temperature to quench free aldehyde groups. Cells were washed three times with PBS, and slides were mounted with Slow-Fade anti-fade reagent (Molecular Probes, Eugene, OR) and observed under a Bio-Rad MR600 confocal microscope at an excitation wavelength of 488 nm.

Preparation of Caveolin-enriched Membrane Fractions-- COS-7 cells were scraped into 2 ml of 2-(N-morpholino)ethanesulfonic acid-buffered saline (MBS; 25 mM 2-(N-morpholino)ethanesulfonic acid, pH 6.5, and 0.15 M NaCl) containing 1% (v/v) Triton X-100. Homogenization was carried out with 10 strokes of a loose-fitting Dounce homogenizer. The homogenate was adjusted to 40% sucrose by the addition of 2 ml of 80% sucrose prepared in MBS and placed at the bottom of an ultracentrifuge tube. A 5-30% linear sucrose gradient was formed above the homogenate and centrifuged at 39,000 rpm for 16-20 h in a SW41 rotor (Beckman Instruments). A light scattering band confined to the 15-20% sucrose region was observed that contained caveolin-1 but excluded most of the other cellular proteins. From the top of each gradient, 1-ml gradient fractions were collected to yield a total of 12 fractions. An equal volume of each gradient fraction was separated by SDS-PAGE and subjected to immunoblot analysis.

Co-Immunoprecipitation-- Cells were washed twice with PBS and lysed for 30 min at 4 °C in a buffer containing 10 mM Tris, pH 8.0, 0.15 M NaCl, 5 mM EDTA, 1% Triton X-100, and 60 mM octyl glucoside. Samples were pre-cleared for 1 h at 4 °C using protein A-Sepharose (20 µl; slurry, 1:1) and subjected to overnight immunoprecipitation at 4 °C using anti-caveolin-1 antibody (10 µl; mAb 2234) and protein A-Sepharose (30 µl; slurry, 1:1). After three washes with the immunoprecipitation buffer, samples were separated by SDS-PAGE (12.5% acrylamide) and transferred to nitrocellulose. Blots were then probed with a polyclonal anti-GFP antibody.

    RESULTS

The Dually Acylated NH2-terminal Region of Gi1alpha Is Sufficient to Target Soluble GFP to the Plasma Membrane in Transfected COS-7 and 293T Cells-- To date, all studies examining the role of lipid modification in the subcellular localization of Gi1alpha have relied on loss of function mutations in the context of the full-length Gi1alpha protein. To determine whether the acylated NH2 terminus of Gi1alpha is sufficient to direct membrane localization, we constructed fusion proteins consisting of full-length wild type Gi1alpha or the first 6, 10, 32, or 122 amino acids of Gi1alpha attached to the NH2 terminus of GFP, a normally cytosolic protein.

Moreover, to define the role of fatty acylation in the specific subcellular localization of the 32aa-GFP chimera, the known palmitoylation site was mutated by replacing cysteine 3 with serine (32aaC3S-GFP). Likewise, the known myristoylation site, glycine 2, was mutated to alanine to generate a nonmyristoylated fusion protein (32aaG2A-GFP). An additional fusion protein (CBD-GFP) was engineered by attaching amino acids 186-200 of Gi1alpha to the NH2 terminus of GFP. Amino acids 186-200 of Gi1alpha contain the known caveolin-binding domain within Gi1 (21).

The characteristics of all these engineered fusion proteins are detailed in Fig. 1. The cDNAs encoding wild type GFP and Gi1alpha -GFP fusions were individually transiently transfected into COS-7 cells. Their expression was analyzed by Western blotting of whole cell lysates using an anti-GFP polyclonal antibody. Fig. 2 shows that 48 h after transfection, the cells produced comparable levels of all of the fusion proteins. In striking contrast, fusion proteins between GFP and the first 6 or 10 amino acids of Gi1alpha were expressed at very low levels (data not shown) and were not further characterized.


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 1.   Schematic illustration of Gi1alpha -GFP fusion proteins used in this study. The full-length sequence (FL) or the first 32 (32aaWT) or 122 (122aa) NH2-terminal amino acids of Gi1alpha were fused to the NH2 terminus of GFP. In 32aaG2A-GFP and 32aaC3S-GFP, each of the 32 amino acid sequences of Gi1alpha fused to GFP was mutagenized to convert glycine 2 to alanine and cysteine 3 to serine, respectively (substitutions are shown as bold letters). In the CBD-GFP chimera, the caveolin-binding domain containing the phenylalanine repeat (underlined; Ref. 21) was NH2 terminally fused to GFP.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 2.   Expression of GFP and Gi1alpha -GFP fusion proteins in COS-7 cells. COS-7 were transiently transfected with different constructs using the calcium phosphate precipitation method. Forty-eight h after transfection, cells were harvested and lysed in Laemmli sample buffer. Lysates were separated by 12.5% SDS-PAGE and immunoblotted with a polyclonal anti-GFP antibody.

Subsequently, fatty acylation patterns of the Gi1alpha -GFP fusions were determined by metabolic radiolabeling of transfected COS-7 cells with [3H]myristate or [3H]palmitate, followed by immunoprecipitation of cell lysates with the GFP antibody. As expected, GFP alone was neither myristoylated nor palmitoylated (data not shown), whereas FL-GFP, 122aa-GFP, and 32aaWT-GFP incorporated both fatty acids (Fig. 3). The 32aaC3S-GFP fusion incorporated [3H]myristate but not [3H]palmitate, whereas 32aaG2A-GFP lacked both fatty acids, thus behaving as the corresponding full-length Gi1alpha G2A mutant, in which myristoylated glycine was required for efficient palmitoylation (26).


View larger version (39K):
[in this window]
[in a new window]
 
Fig. 3.   Fatty acylation of the Gi1alpha -GFP fusion proteins. Transfected COS-7 cells were metabolically labeled for 4 h with either [3H]palmitic acid (Pal) or [3H]myristic acid (Myr). Cell lysates were immunoprecipitated with an anti-GFP antibody and analyzed by SDS-PAGE and fluorography. To enhance signal detection, fluorographed gels were miniaturized as described under "Experimental Procedures."

The subcellular localization of GFP and each of the Gi1alpha -GFP fusion proteins was next examined by fractionating postnuclear COS-7 cell homogenates into cytosolic (Fig. 4, S) and membrane (Fig. 4, P) fractions by ultracentrifugation at 200,000 × g. Each fraction was then analyzed by immunoblotting with an anti-GFP antibody.


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 4.   Subcellular distribution of GFP and Gi1alpha -GFP fusion proteins in transfected COS-7 cells. Postnuclear supernatants of transfected COS-7 cells were fractionated by ultracentrifugation at 200,000 × g into soluble (S) and particulate (P) fractions. Partitioning of proteins between the fractions was determined by SDS-PAGE and immunoblotting with an anti-GFP antibody.

As expected, GFP was entirely soluble, whereas FL-GFP, 122aa-GFP, and 32aaWT-GFP were primarily concentrated in the particulate fraction (80-90%; Fig. 4). In contrast, the amount of nonpalmitoylated 32aaC3S-GFP was greatly increased within the soluble fraction (>50%; Fig. 4). An even greater shift was observed with 32aaG2A-GFP, which is neither myristoylated nor palmitoylated, because ~90% of this protein was detected in the soluble fraction, as was CBD-GFP (Fig. 4). We conclude from these experiments that the NH2-terminal Gi1alpha sequence is sufficient to target a cytosolic protein to cellular membranes and that myristic and palmitic acids cooperatively affect membrane binding. The results observed with CBD-GFP fusion suggest that binding to caveolin-1 and anchorage to cellular membranes are expressed by distinct domains of the Gi1alpha protein. It is worth noting that the particulate fraction in this assay contains total cell membranes, including plasma membrane and intracellular membranes. Thus, changes in the distribution among various cell membrane compartments will not be appreciated unless a morphological analysis of transfected cells is performed.

To investigate the intracellular localization of the various Gi1alpha -GFP fusion proteins, we took advantage of the spontaneous fluorescence of GFP. 293T cells expressing wild type GFP and the Gi1alpha -GFP fusions were fixed and examined by laser scanning confocal microscopy. The micrographs presented in Fig. 5 illustrate that although GFP was cytosolic, it gained a plasma membrane localization after fusion with full-length Gi1alpha or its NH2-terminal 122- and 32-amino acid sequences.


View larger version (57K):
[in this window]
[in a new window]
 
Fig. 5.   Subcellular targeting of Gi1alpha -GFP fusion proteins in transfected 293T cells. 293T cells expressing wild type GFP or Gi1alpha -GFP fusion proteins were fixed with 2% (w/v) paraformaldehyde 48 h after transfection. Cells expressing endogenous Gi1alpha were stained with a rabbit antiserum (I1C) raised against a synthetic peptide corresponding to amino acids 160-169 of the Gi1alpha subunit. GFP fluorescence and Gi1alpha indirect immunofluorescence were visualized by confocal microscopy at an excitation wavelength of 488 nm.

Interestingly, FL-GFP, 122aa-GFP, and 32aaWT-GFP exhibited the same pattern of cellular distribution as wild type Gi1alpha visualized by indirect immunofluorescence staining of 293T cells with a Gi1alpha anti-serum. In contrast, nonacylated 32aaG2A-GFP showed a diffuse cytosolic staining (Fig. 5), whereas nonpalmitoylated 32aaC3S-GFP exhibited a hybrid distribution, as illustrated by the staining of both cell edges and the cytoplasm. The fluorescence associated with the CBD-GFP fusion was diffuse, thus confirming its localization primarily within the cytosol, in agreement with our biochemical experiments (see Fig. 4). Mock-transfected 293T cells showed no detectable fluorescence (data not shown). These results clearly demonstrate that the first 32 amino acids of Gi1alpha contain information that is sufficient to specify a plasma membrane localization, provided that fatty acylation is successfully completed.

Lipid Modification of the NH2-terminal Region of Gi1alpha Is Required to Deliver a GFP Fusion Protein to Caveolin-enriched Membrane Domains in COS-7 Cells-- Recently, it has been shown that heterotrimeric G-protein subunits, as well as a number of other signaling molecules, are concentrated within a distinct subcompartment of the plasma membrane known as caveolae (7-9).

Due to their high content of cholesterol and glycosphingolipids, caveolar membranes are resistant to extraction at 4 °C by nonionic detergents such as Triton X-100 and float on bottom-loaded sucrose density gradients. Using a well-defined procedure that combines both of these physicochemical properties to separate low density, Triton-insoluble membranes containing caveolin-1 (7) from the bulk of cellular membranes and cytosolic proteins, we analyzed by Western blotting the content of GFP, Gi1alpha , and Gi1alpha -GFP fusions in sucrose density gradient fractions obtained from transfected COS-7 cells.

Caveolin-1, a structural protein of caveolar membranes, was used as a marker protein for the distribution of these detergent-resistant membrane domains. As shown in Fig. 6A, the bulk of cellular proteins, including soluble polypeptides, were concentrated in the bottom, high density fractions (40% sucrose layer of the gradient; lanes 9-12), whereas caveolin-1 immunoreactivity was exclusively detected in the caveolae fractions (~10-20% sucrose layer of the gradient; lanes 4 and 5).


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 6.   Subcellular fractionation of COS-7 cells expressing Gi1alpha -GFP fusions. COS-7 cells transfected with Gi1alpha , GFP, and each of the Gi1alpha -GFP fusion proteins were extracted in 1% (v/v) Triton X-100 at 4 °C and subjected to ultracentrifugation on sucrose density gradients. One-ml fractions collected from the top of the gradients were separated by SDS-PAGE and transferred to nitrocellulose. Fractions 1-4 (lanes 1-4) are the 5% sucrose layer, and fractions 5-8 (lanes 5-8) are the 30% sucrose layer. Fractions 9-12 (lanes 9-12), containing 40% sucrose, represent the "loading zone" of these bottom-loaded flotation gradients and contain the bulk of the cellular membrane and cytosolic proteins as described previously (14). Upper panel, Ponceau S staining of the total cellular proteins; lower panels, immunoblotting with anti-caveolin-1, anti-Gi1alpha , or anti-GFP antibodies to visualize the distribution of endogenously expressed caveolin-1 and transfected Gi1alpha and Gi1alpha -GFP fusion proteins.

Fig. 6B shows that FL-GFP, 122aa-GFP, and 32aaWT-GFP fusions exhibited a distribution pattern equivalent to that of wild type Gi1alpha , distributing between both caveolin-containing fractions as well as fractions 9-12 (lanes 9-12). The palmitoylation-defective 32aaC3S-GFP fusion had a similar distribution; however, compared with the wild type, significantly less of the fusion protein was detected in the low density caveolae fractions and more was present in the soluble, higher density fractions, as might be anticipated by its increased solubility (see Fig. 4).

Accordingly, fully soluble 32aaG2A-GFP and CBD-GFP fusions were completely excluded from the caveolin-containing fractions and were concentrated at the bottom of the gradient, behaving essentially as soluble GFP alone. These observations suggest that amino acids 1-32 of Gi1alpha , which contain the myristoyl and palmitoyl moieties, encode the complete address signal for subcellular targeting of the Gi1alpha polypeptide.

Lipid Modifications Are Required for the Binding of Gi1alpha to Caveolin-- Caveolin interacts directly with Galpha subunits, preferentially recognizing their inactive conformation (13). Thus, it has been suggested that caveolin functions as a scaffolding protein to spatially organize certain caveolin-interacting proteins within caveolae membranes. The scaffolding domain of caveolin consists of a 20-amino acid stretch (residues 82-101) within the NH2-terminal cytoplasmic domain of caveolin-1 (27). A consensus sequence for caveolin binding has been deduced in many caveolae-associated polypeptides, including Galpha subunits (21). Lipid modification of Galpha subunits is not required for interaction with caveolin-1 in vitro (13); however, it remains unknown whether lipid modification of Galpha subunits is required for interaction with caveolin-1 in vivo.

In this study, we wanted to examine whether the NH2 terminus of Gi1alpha , although located a distance from the caveolin-binding motif (residues 186-200 of Gi1alpha ), might influence interactions with caveolin-1 in vivo. For this purpose, we immunoprecipitated lysates of COS-7 cells transfected with various Gi1alpha -GFP fusions with a specific mAb probe that recognizes the extreme NH2 terminus of caveolin-1 and analyzed the composition of these precipitates by Western blotting with a GFP-specific antibody.

Fig. 7A shows that FL-GFP, 122aa-GFP, and 32aaWT-GFP clearly co-immunoprecipitated with caveolin-1. In striking contrast, mutant fusions 32aaC3S-GFP, 32aaG2A-GFP, and GFP alone failed to co-immunoprecipitate with caveolin-1. Therefore, even in the absence of the known Gi1alpha caveolin-binding domain, as in 122aa-GFP and 32aaWT-GFP fusions, the NH2-terminal domain of Gi1alpha played a key role in the association of Gi1alpha with caveolin-1, provided that it is correctly dually acylated.


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 7.   Interaction of Gi1alpha -GFP fusion proteins with caveolin-1. A, detergent extracts of transfected COS-7 cells were immunoprecipitated with anti-caveolin-1 mAb 2234 IgG and protein A-Sepharose beads. These immunoprecipitates were subjected to SDS-PAGE and analyzed by Western blotting with anti-GFP antibody. B, COS-7 cell extracts contained equivalent amounts of each of the Gi1alpha -GFP fusion proteins and of caveolin-1, as determined by Western blot analysis before immunoprecipitation.

Palmitoylation of Caveolin-1 Is Required for Its Recognition of the Lipid-modified NH2-terminal Domain of Gi1alpha -- Caveolin-1 is palmitoylated on three COOH-terminal cysteines, more specifically, residues 133, 143, and 156 (22). The loss of palmitoyl moieties does not affect the membrane insertion of the caveolin-1 polypeptide, its targeting to caveolae membranes, or its ability to form high molecular weight homo-oligomers (22, 28). Palmitoylation of caveolin-1 protects caveolin-1 homo-oligomers from dissociation by SDS denaturation during boiling. However, the physiological relevance of this finding remains unknown.

To determine whether 32aaWT-GFP binds equally well to palmitoylated or nonpalmitoylated forms of caveolin-1, we co-transfected COS-7 cells with this GFP fusion together with either wild type caveolin-1 or a mutant form of caveolin-1 that lacks all three palmitoylation sites (C133S, C143S, and C156S). Extracts of the transfected cells were then prepared and immunoprecipitated with a specific mAb directed against the unique NH2 terminus of caveolin-1 (mAb 2234). These caveolin-1 immunoprecipitates were separated by SDS-PAGE and subjected to immunoblot analysis with a specific GFP antibody. Interestingly, we observed that the 32aaWT-GFP fusion co-immunoprecipitated only from cells expressing wild type caveolin-1 (Fig. 8A), suggesting that the proper binding of Gi1alpha requires palmitoylation of caveolin-1.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 8.   Palmitoylation of caveolin-1 is required for interaction with Gi1alpha . 32aaWT-GFP was co-transfected in COS-7 cells with the wild type form of caveolin-1 (cav-1 WT) or with the palmitoylation-defective caveolin-1 mutant (cav-1 Cys-). A, detergent extracts of transfected cells were immunoprecipitated with anti-caveolin-1 mAb 2234 IgG and protein A-Sepharose beads. Immunoprecipitates were subjected to SDS-PAGE and assayed by Western blotting with anti-GFP antibody. B, Western blot analysis of cell extracts before immunoprecipitation with anti-GFP and anti-caveolin-1 antibodies shows that equivalent levels of 32aaWT-GFP and of wild type and palmitoylation-defective caveolin-1 were expressed in COS-7 cells after transfection.


    DISCUSSION

There is a general consensus that the dually acylated NH2 terminus of Gi/Go/Gz alpha  subunits is required for their attachment to the cytoplasmic leaflet of the plasma membrane. This is based mainly on the observation that simultaneous mutations of glycine 2 and cysteine 3, respectively, the acceptor sites for the attachment of myristate and palmitate, considerably shift Galpha subunits to the soluble fraction (26, 29, 30). Similarly, Src-like NRTKs (such as Lck and Fyn) share the same NH2-terminal acylation motif with Gi/Go/Gz alpha  subunits and an extra palmitoylated cysteine at position 5 or 6, respectively, and their membrane association is prevented by mutation of these key sites of fatty acylation (3).

However, in the case of Lck and Fyn, the NH2-terminal domain plays a more complex role than merely serving as a membrane-anchoring device. Mutational analysis has demonstrated that the association of Lck and Fyn with the glycosylphosphatidylinositol-anchored membrane proteins mapped to the first 10 amino acids of the NRTKs, and the addition of myristate and palmitate is required for this reciprocal interaction (31). Subsequent studies have highlighted the key role of palmitoylated cysteines in targeting Lck and Fyn to Triton-insoluble, glycolipid-enriched, membrane subdomains (DIGs; Refs. 32-35) and in sorting these polypeptides to different subcellular membrane compartments (36). Thus, the NH2-terminal domain of NRTKs accomplishes the dual function of targeting these polypeptides to a final membrane compartment and stabilizing their association with the cytoplasmic leaflet of the lipid bilayer.

By analogy with NRTKs, a similar role for the dually acylated NH2-terminal domain of Gi/Go/Gz alpha  subunits in targeting has been postulated. This view is supported by the finding that Galpha subunits, as well as Src-like NRTKs, can be found in flattened (termed DIGs or rafts) or invaginated (termed caveolae) specializations of the plasma membrane, which are rich in cholesterol and glycosphingolipids (7-9). In contrast, earlier reports have suggested that membrane anchoring and subcellular targeting of Gi alpha  subunits are contained within distinct protein domains. The COOH terminus plays a role in the differential targeting of Gi2alpha and Gi3alpha subunits to the plasma and Golgi membranes, respectively, because intracellular localization of Gi2alpha /Gi3alpha chimeras was dependent on which COOH-terminal half was used (37).

Here we consider the issue that the NH2 terminus of dually acylated Galpha subunits also contributes to their subcellular targeting. We analyzed the ability of various NH2-terminal extensions of Gi1alpha to act as a membrane-anchoring and targeting signal for a normally soluble carrier protein, namely, GFP. The subcellular targeting of each Gi1alpha -GFP fusion construct was evaluated after transient expression in transfected cells using confocal microscopy and biochemical techniques. The fluorescence associated with the full-length Gi1alpha -GFP fusion protein localized at the edges of transfected cells behaving as wild type untagged Gi1alpha , suggesting that the GFP reporter did not interfere with the proper localization of Gi1alpha . Moreover, the full-length Gi1alpha -GFP fusion protein co-localized with caveolin-1, a protein marker for caveolae membranes, in low buoyancy fractions purified by sucrose gradient centrifugation and was co-immunoprecipitated by caveolin-1 antibodies.

The same distribution pattern was exhibited by 122aa-GFP and 32aaWT-GFP fusions, indicating that the first 32 amino acids of Gi1alpha contain the signal to deliver polypeptides to low density, caveolin-enriched, plasma membrane domains and to interact with caveolin-1. We also attempted to define the targeting domain of Gi1alpha in greater detail by fusing only the first 6 or 10 residues to GFP. Unfortunately, these GFP fusions were expressed at much lower levels than 32aaWT-GFP in COS-7 cells (data not shown). This may reflect the structural instability of these shorter Gi1alpha fusions because 6 or 10 amino acids would not be long enough to allow the formation of the 30-amino acid residue NH2-terminal alpha -helix present in wild type Gi1alpha (38).

As with NRTKs, the cellular targeting of 32aaWT-GFP was strictly dependent on fatty acylation. The 32aaG2A-GFP chimera, which lacked both fatty acids, was diffusely localized within the cytoplasm and behaved as wild type GFP. In contrast, the palmitoylation-defective 32aaC3S-GFP retained some membrane avidity due to the presence of myristate and displayed a reduced association with caveolin-enriched sucrose density fractions.

Interestingly, the binding of nonpalmitoylated 32aaC3S-GFP to caveolin-1 was completely abrogated, suggesting that: (i) co-fractionation with caveolin on sucrose gradients does not necessarily imply a direct physical interaction between the two polypeptides, and (ii) palmitoylation of cysteine 3 is an absolute prerequisite for the binding of Gi1alpha to caveolin in vivo. This may explain the results of Huang et al. (9), who failed to detect a substantial direct interaction between recombinant myristoylated but palmitoylation-defective Goalpha and caveolin-1. However, it contrasts with the observed in vitro interaction between caveolin-1 and palmitoylated Goalpha or Gi2alpha expressed by baculovirus-infected Sf9 cells (13).

Using the caveolin-1 scaffolding domain as a receptor to select caveolin-binding peptide ligands from peptide sequences displayed at the surface of the bacteriophage (phage display libraries), two related caveolin-binding motifs have been identified (phi Xphi XXXXphi and phi XXXXphi XXphi , with phi  representing aromatic amino acids Trp, Phe, or Tyr) (21). These motifs exist within most caveolae-associated proteins, including Gi1alpha (21). Interestingly, when residues 186-200 of Gi1alpha containing the defined motif for interaction with caveolin-1 (21) were fused to GFP, the resulting CBD-GFP chimera did not co-immunoprecipitate with caveolin-1. This may suggest that the fatty acylation of Gi1alpha , by promoting an interaction with lipid and/or protein component(s) of the plasma membrane bilayer, must precede caveolin-1 recognition by the caveolin-binding domain in vivo. This implies a two-step mechanism for the caveolar targeting of Gi1alpha . This proposed mechanism is summarized schematically in Fig. 9. In the first step, mutual interaction of palmitic acid residues in Gi1alpha and caveolin-1 are responsible for the binding of Gi1alpha to caveolin-1. In a second step, this interaction is stabilized by the binding of the caveolin-binding domain of Gi1alpha to the scaffolding domain of caveolin-1. A similar conclusion has been reached regarding the interaction of Ras with caveolin-1 (39). Lipid modification of Ras by prenylation is required for its correct targeting to caveolae in vivo but is not required for its in vitro interaction with caveolin-1 (39).


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 9.   Schematic illustration of the caveolar targeting of Gi1alpha . In Step 1, palmitic acid of Gi1alpha is responsible for binding to the plasma membrane bilayer and to caveolin-1 oligomers. Palmitic acid residues in the COOH-terminal of caveolin-1 directly interact with palmitic acid residues in Gi1alpha . In Step 2, the caveolin-binding domain of Gi1alpha interacts with the scaffolding domain of caveolin-1, stabilizing the mutual interaction.

The unique role of palmitoylation in mediating the association of Gi1alpha with caveolin-1 is important because, unlike myristoylation, palmitoylation is a reversible modification. For example, in the case of Gsalpha (40-42) and Gq/11alpha (43), regulation of palmitoylation by direct or receptor-mediated activation has been demonstrated experimentally. Our results are also consistent with the previous observation that mutationally activated Gsalpha showing an accelerated rate of depalmitoylation (41) fails to interact with recombinant caveolin-1, as compared with its wild type counterpart, nonmutated Gsalpha (13).

Caveolin-1 can associate with itself to form Triton-insoluble high molecular mass homo-oligomers (300-400 kDa) in vivo as well as in vitro (28, 44). It has been proposed that caveolin-1 oligomers complexed with cholesterol and glycosphingolipids can form a matrix within membrane rafts, or caveolae, acting as a scaffold for lipid-modified signaling proteins (17). Although the oligomerization region of caveolin has been mapped to residues 61-101 of the NH2-terminal cytoplasmic domain (44), recent observations (28) have shown that complete maturation of these high molecular mass complexes requires the palmitoylation of three cysteine residues located at positions 133, 143, and 156 within the COOH-terminal cytoplasmic tail. This COOH-terminal region of caveolin-1 has also been implicated in mediating interactions between individual caveolin-1 homo-oligomers, forming a caveolin-1 network or patch within the plasma membrane (17). Here, we show that the 32aaWT-GFP chimera, when co-expressed in COS-7 cells with a mutant form of caveolin-1 that lacks all three palmitoylation sites, can no longer be co-immunoprecipitated with caveolin-1 IgG, indicating a loss of interaction between the two polypeptides. This finding suggests that palmitoylation of caveolin-1 oligomers is necessary for complex formation with inactive Galpha , and perhaps with other signaling molecules as well, within caveolae membranes in vivo.

In conclusion, our results demonstrate that both membrane-anchoring and targeting functions are encoded by the dually acylated NH2-terminal domain of Gi1alpha and that palmitoylation of Gi1alpha cysteine 3 plays a key role by facilitating the interaction with caveolin-1. A recent study (45) has reached similar conclusions for Gzalpha , suggesting specific roles for myristoylation and palmitoylation in membrane targeting. They observed that the attachment of myristate cooperates with beta gamma dimer binding to promote the stable association of Gzalpha with membranes and that the addition of palmitate confers specific localization at the plasma membrane. However, these authors did not examine the interaction of Gzalpha with caveolae or caveolins. Thus, regulated palmitoylation of Galpha , on one hand, and caveolin-1, on the other, adds further potential handles to control G-protein-mediated signal transduction.

    FOOTNOTES

* This work was supported by grants from the Consiglio Nazionale delle Ricerche (Target Project on Biotechnology) and Ministero dell'Università e Ricerca Scientifica e Tecnologica (to M. P.) and from the Wellcome trust (to G. M. and M. P.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

** Supported by National Institutes of Health Grant ROI-CA-80250 and by grants from the Charles E. Culpeper Foundation, the G. Harold and Leila Y. Mathers Charitable Foundation, and the Sidney Kimmel Foundation for Cancer Research.

Dagger Dagger To whom correspondence should be addressed: Dept. of Pharmacology, School of Medicine, University of Milan, Via Vanvitelli 32, 20129 Milan, Italy. Tel.: 39-2-70146282; Fax: 39-2-70146371; E-mail: marco.parenti{at}unimi.it.

    ABBREVIATIONS

The abbreviations used are: NRTK, non-receptor tyrosine kinase; GFP, green fluorescent protein; mAb, monoclonal antibody; PAGE, polyacrylamide gel electrophoresis; TBST, Tris-buffered saline/Tween 20; Galpha , G-protein alpha  subunit; PBS, phosphate-buffered saline.

    REFERENCES
Top
Abstract
Introduction
References
  1. Parenti, M., Viganó, M. A., Newman, C. M. H., Milligan, G., and Magee, A. I. (1993) Biochem. J. 291, 349-353[Medline] [Order article via Infotrieve]
  2. Koegl, M., Zlatkine, P., Ley, S. C., Courtneidge, S. A., and Magee, A. I. (1994) Biochem. J. 303, 749-753[Medline] [Order article via Infotrieve]
  3. Alland, L., Peseckis, S. M., Atherton, R. E., Berthiaume, L., and Resh, M. D. (1994) J. Biol. Chem. 269, 16701-16705[Abstract/Free Full Text]
  4. Grassie, M. A., McCallum, J. F., Guzzi, F., Magee, A. I., Milligan, G., and Parenti, M. (1994) Biochem. J. 302, 913-920[Medline] [Order article via Infotrieve]
  5. Tu, Y., Wang, J., and Ross, E. M. (1997) Science 278, 1132-1135[Abstract/Free Full Text]
  6. Wise, A., Grassie, M. A., Parenti, M., Lee, M., Rees, S., and Milligan, G. (1997) Biochemistry 36, 10620-10629[CrossRef][Medline] [Order article via Infotrieve]
  7. Sargiacomo, M., Sudol, M., Tang, Z.-L., and Lisanti, M. P. (1993) J. Cell Biol. 122, 789-807[Abstract]
  8. Chang, W. J., Ying, Y., Rothberg, K., Hooper, N., Turner, A., Gambliel, H., De Gunzburg, J., Mumby, S., Gilman, A., and Anderson, R. G. W. (1994) J. Cell Biol. 126, 127-138[Abstract]
  9. Huang, C., Hepler, J. R., Chen, L. T., Gilman, A. G., Anderson, R. G. W., and Mumby, S. M. (1997) Mol. Biol. Cell 8, 2365-2378[Abstract/Free Full Text]
  10. Simons, K., and Ikonen, E. (1997) Nature 387, 569-572[CrossRef][Medline] [Order article via Infotrieve]
  11. Brown, R. E. (1998) J. Cell Sci. 111, 1-9[Abstract/Free Full Text]
  12. Rothberg, K. G., Heuser, J. E., Donzell, W. C., Ying, Y.-S., Glenney, J. R., and Anderson, R. G. W. (1992) Cell 68, 673-682[Medline] [Order article via Infotrieve]
  13. Li, S., Okamoto, T., Chun, M., Sargiacomo, M., Casanova, J. E., Hansen, S. H., Nishimoto, I., and Lisanti, M. P. (1995) J. Biol. Chem. 270, 15693-15701[Abstract/Free Full Text]
  14. Sargiacomo, M., Scherer, P. E., Tang, Z.-L., Kubler, E., Song, K. S., Sanders, M. C., and Lisanti, M. P. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 9407-9411[Abstract]
  15. de Weerd, W. F. C., and Leeb-Lundberg, L. M. F. (1997) J. Biol. Chem. 272, 17858-17866[Abstract/Free Full Text]
  16. Feron, O., Smith, T. W., Michel, T., and Kelly, R. A. (1997) J. Biol. Chem. 272, 17744-17748[Abstract/Free Full Text]
  17. Okamoto, T., Schlegel, A., Scherer, P. E., and Lisanti, M. P. (1998) J. Biol. Chem. 273, 5419-5422[Free Full Text]
  18. Song, K. S., Sargiacomo, M., Galbiati, F., Parenti, M., and Lisanti, M. P. (1997) Cell. Mol. Biol. 43, 293-303
  19. Parolini, I., Sargiacomo, M., Lisanti, M. P., and Peschle, C. (1996) Blood 87, 3783-3794[Abstract/Free Full Text]
  20. Feron, O., Belhassen, L., Kobzik, L., Smith, T. W., Kelly, R. A., and Michel, T. (1996) J. Biol. Chem. 271, 22810-22814[Abstract/Free Full Text]
  21. Couet, J., Li, S. W., Okamoto, T., Ikezu, T., and Lisanti, M. P. (1997) J. Biol. Chem. 272, 6525-6533[Abstract/Free Full Text]
  22. Dietzen, D. J., Hastings, W. R., and Lublin, D. M. (1995) J. Biol. Chem. 270, 6838-6842[Abstract/Free Full Text]
  23. Laemmli, U. K. (1970) Nature 227, 680-685[Medline] [Order article via Infotrieve]
  24. Bonner, W. M., and Laskey, R. A. (1986) Eur. J. Biochem. 46, 83-88[Medline] [Order article via Infotrieve]
  25. Magee, A. I., Wootton, J., and De Bony, J. (1995) Methods Enzymol. 250, 330-336[Medline] [Order article via Infotrieve]
  26. Galbiati, F., Guzzi, F., Magee, A. I., Milligan, G., and Parenti, M. (1994) Biochem. J. 303, 697-700[Medline] [Order article via Infotrieve]
  27. Li, S., Couet, J., and Lisanti, M. P. (1996) J. Biol. Chem. 271, 29182-29190[Abstract/Free Full Text]
  28. Monier, S., Dietzen, D. J., Hastings, W. R., Lublin, D. M., and Kurzchalia, T. V. (1996) FEBS Lett. 388, 143-149[CrossRef][Medline] [Order article via Infotrieve]
  29. Mumby, S. M., Kleuss, C., and Gilman, A. G. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 2800-2804[Abstract]
  30. Wilson, P. T., and Bourne, H. R. (1995) J. Biol. Chem. 270, 9667-9675[Abstract/Free Full Text]
  31. Shenoy-Scaria, A. M., Timson Gauen, L. K., Kwong, J., Shaw, A. S., and Lublin, D. M. (1993) Mol. Cell. Biol. 13, 6385-6392[Abstract]
  32. Rodgers, W., Crise, B., and Rose, J. K. (1994) Mol. Cell. Biol. 14, 5384-5391[Abstract]
  33. Shenoy-Scaria, A. M., Dietzen, D. J., Kwong, J., Link, D. C., and Lublin, D. M. (1994) J. Cell Biol. 126, 353-363[Abstract]
  34. Wolven, A., Okamura, H., Rosenblatt, Y., and Resh, M. D. (1997) Mol. Biol. Cell 8, 1159-1173[Abstract]
  35. Zlatkine, P., Mehul, B., and Magee, A. I. (1997) J. Cell Sci. 110, 673-679[Abstract/Free Full Text]
  36. Bijlmakers, M.-J. J. E., Isobe-Nakamura, M., Ruddock, L. J., and Marsh, M. (1997) J. Cell Biol. 137, 1029-1040[Abstract/Free Full Text]
  37. de Almeida, J. B., Holtzman, E. J., Peters, P., Ercolani, L., Ausiello, D. A., and Stow, J. L. (1994) J. Cell Sci. 107, 507-515[Abstract/Free Full Text]
  38. Lambright, D. G., Sondek, J., Bohm, A., Skiba, N. P., Hamm, H. E., and Sigler, P. B. (1996) Nature 379, 311-319[CrossRef][Medline] [Order article via Infotrieve]
  39. Song, K. S., Li, S., Okamoto, T., Quilliam, L. A., Sargiacomo, M., and Lisanti, M. P. (1996) J. Biol. Chem. 271, 9690-9697[Abstract/Free Full Text]
  40. Degtyarev, M. Y., Spiegel, A. M., and Jones, T. L. Z. (1993) J. Biol. Chem. 268, 23769-23772[Abstract/Free Full Text]
  41. Wedegaertner, P. B., and Bourne, H. R. (1994) Cell 77, 1063-1070[Medline] [Order article via Infotrieve]
  42. Mumby, S. M., Kleuss, C., and Gilman, A. G. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 2800-2804[Abstract]
  43. Stanislaus, D., Janovick, J. A., Brothers, S., and Conn, P. M. (1997) Mol. Endocrinol. 11, 738-746[Abstract/Free Full Text]
  44. Sargiacomo, M., Scherer, P. E., Tang, Z.-L., Kubler, E., Song, K. S., Sanders, M. C., and Lisanti, M. P. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 9407-9411[Abstract]
  45. Morales, J., Fishburn, C. S., Wilson, P. T., and Bourne, H. R. (1998) Mol. Biol. Cell 9, 1-14[Abstract/Free Full Text]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.